Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002371 | The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine | PHASE3 | COMPLETED | 80 | — | — | Jun 1, 1996 | Dec 1, 1997 | May 4, 2011 | 8 | United States, Canada +1 |
| Name | Type | Description |
|---|---|---|
| Indinavir sulfate | DRUG | - |
| Lamivudine | DRUG | - |
| Stavudine | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion Criteria Patients must have: * At least six months of prior cumulative ZDV therapy. * Qualifying plasma HIV RNA count of \>= 4 log10 copies/ml obtained within 2 weeks of randomization. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms or conditions ...